KOSDAQBiotech & Pharma308430

Cellbion

₩14,600▲ 2.03%2026-10-02 close

Market Cap

₩188.7B

Turnover

₩400M

Volume

30,000 shares

Shares out.

12.9M

PER

21.2×

PBR

4.5×

EPS

₩602

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Cellbion Nears Commercialization, Losses Persist

Cellbion is pursuing conditional domestic approval for its prostate cancer radiopharmaceutical 'pocuvotide,' while its annual and quarterly results remain deep in operating losses.

1
The core pipeline '177Lu-pocuvotide' was filed for conditional marketing approval with Korea's MFDS in December 2025, and a separate Phase 3 IND was also filed on June 30, 2026.
2
Phase 2 data presented at 2026 ASCO/ASCO-GU showed an objective response rate of 35.9% and radiographic progression-free survival of 11.04 months, both favorable versus the competing agent.
3
Annual revenue remains small at roughly KRW 2 billion, while the operating loss widened from KRW -5.04 billion in 2023 to KRW -8.24 billion in 2025.
4
Owner net income in Q2 2026 swung sharply to +KRW 14.40 billion despite a widening operating loss, a divergence that appears driven by non-operating items and warrants careful interpretation.
5
The company is collaborating with MSD on a Keytruda combination trial, while ongoing external financing via convertible bonds and convertible preferred shares also raises dilution considerations.

Business structure

Cellbion is a radiopharmaceutical (RPT) specialist founded in 2010, focused on new drug development, generic pharmaceuticals, and CDMO businesses.

Its core pipeline is 'pocuvotide,' a theranostic (combined diagnostic and therapeutic) radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), comprising the diagnostic Ga-68-NGUL and the therapeutic Lu-177-DGUL (177Lu-pocuvotide), aimed at metastatic castration-resistant prostate cancer (mCRPC) patients.

The company's core competency is its proprietary DGUL ligand technology, which precisely identifies PSMA and carries the radioisotope lutetium-177 to cancer cells, designed to enhance in-vivo stability and reduce exposure to major organs.

The market is currently dominated globally by Novartis' Pluvicto, positioning Cellbion as a domestic challenger. In Korea, Futurechem has secured approval for a similar radiopharmaceutical candidate, FC705, as Korea's 43rd domestically developed new drug, forming a competitive landscape.

With global pharma MSD (Merck), the company signed a collaboration agreement in February 2025 for a Keytruda combination trial involving PSMA-DGUL (pocuvotide sacetraacetan), and a Phase 1 combination trial protocol was approved in September of the same year.

On the supply side, domestic developers including Novartis and Futurechem are reportedly preparing local production capacity for the radioisotope, an industry-wide move to reduce reliance on imports that includes Cellbion.

As commercial sales have yet to materialize meaningfully, the company's value hinges largely on clinical and regulatory progress of its pipeline.

Earnings trend

Quarterly revenue · Operating profit

₩400M-₩2.1B25Q2₩700M-₩2B25Q3₩400M-₩2.5B25Q4₩600M-₩2.4B26Q1₩500M-₩2.6B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩1.5B-₩5B2023₩2.3B-₩7.1B2024₩1.9B-₩8.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩400M	-₩2.1B	−515.3%
2025Q3	₩700M	-₩2B	−294.1%
2025Q4	₩400M	-₩2.5B	−657.6%
2026Q1	₩600M	-₩2.4B	−399.0%
2026Q2	₩500M	-₩2.6B	−559.9%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2023	₩1.5B	-₩5B	-₩3.6B	−342.8%	−48.5%	51.3%
2024	₩2.3B	-₩7.1B	-₩7.3B	−311.7%	−24.6%	16.3%
2025	₩1.9B	-₩8.2B	-₩7.6B	−423.9%	−33.2%	54.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Cellbion's annual revenue rose from KRW 1.47 billion in 2023 to KRW 2.29 billion in 2024 before declining to KRW 1.95 billion in 2025, showing no stable growth trajectory yet.

The operating loss widened each year, from KRW -5.04 billion in 2023 to KRW -7.14 billion in 2024 and KRW -8.24 billion in 2025, and owner net loss similarly grew from KRW -3.63 billion in 2023 to KRW -7.27 billion in 2024 and KRW -7.57 billion in 2025.

This reflects continually rising R&D spending tied to clinical and regulatory activities ahead of commercialization. Operating cash flow also showed accelerating net outflows, from KRW -3.94 billion in 2023 to KRW -4.78 billion in 2024 and KRW -5.55 billion in 2025, indicating a faster pace of cash burn.

On a quarterly basis, revenue fluctuated between KRW 0.38 billion and KRW 0.68 billion from Q2 2025 through Q1 2026, while the operating loss steadily widened from around KRW -2.0 billion to KRW -2.6 billion.

In Q2 2026, however, the operating loss widened further to KRW -2.64 billion, yet owner net income swung sharply positive to KRW 14.40 billion, a divergence so large it appears attributable to non-operating factors.

As a result, the sum of owner net income over the trailing four quarters (Q3 2025-Q2 2026) came to a positive KRW 7.75 billion, superficially suggesting a turnaround, even though operating results remained cumulatively in loss over the same period, warranting caution in interpreting the quality of this earnings figure.

The debt ratio fell from 51.3% in 2023 to 16.3% in 2024 before rising back to 54.5% in 2025, reflecting repeated cycles of external financing and capital changes.

Industry analysis

Radioligand therapy (RLT), or theranostics, is considered a field reshaping the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC).

The market is currently dominated globally by Novartis' Pluvicto, which represents both a barrier to entry and a significant opportunity for later-stage domestic and international developers.

In Korea, Futurechem has secured approval for a similar radiopharmaceutical as the country's 43rd domestically developed new drug, forming a competitive landscape with Cellbion, with rivalry continuing over the title of Korea's first domestically commercialized RPT.

Given the short half-life inherent to radiopharmaceuticals, rapid and stable raw material supply is essential, and domestic developers including Novartis, Futurechem, and Cellbion are reportedly all preparing local production infrastructure, reflecting an industry-wide push to reduce reliance on imports.

Once such infrastructure is complete, more stable supply and cost savings are expected, which could also affect the price competitiveness of domestic developers.

On the regulatory front, Korea's MFDS has designated related candidates as orphan drugs and global innovative products eligible for expedited review, creating an institutional environment where conditional marketing approval can be granted based on Phase 2 data alone.

Still, given that large global pharma companies lead the market, domestic developers must clear additional hurdles after domestic launch, including reimbursement listing and global out-licensing, to secure a stable revenue base.

Outlook

Based on the Phase 1/2 clinical study report (CSR) received on December 12, 2025, Cellbion filed for conditional marketing approval of '177Lu-pocuvotide' with Korea's MFDS on December 30, 2025, and the company expects domestic launch within 2026 if the expedited review proceeds smoothly.

The company presented Phase 2 results in a poster at ASCO-GU in February 2026, and at the ASCO 2026 annual meeting in May disclosed additional survival endpoints and subgroup analyses, including a monotherapy radiographic progression-free survival (rPFS) of 11.04 months.

However, as of reports from May 2026, the conditional approval process was still proceeding as planned, and no disclosure confirming final approval has been identified as of the search date, so the actual approval and launch timing requires further confirmation.

Separately, on June 30, 2026, the company filed a domestic Phase 3 IND with the MFDS for mCRPC patients, a multicenter, open-label, randomized trial to be conducted at institutions including Seoul National University Hospital, comparing best supportive care/standard of care alone versus combination with Lu-177 DGUL across a total of 150 patients assigned 1:1.

With MSD (Merck), the company has a clinical trial collaboration and supply agreement for a Keytruda combination regimen; a related Phase 1 trial protocol was approved in September 2025, and after some delay in trial initiation, first dosing was recently reported to have occurred.

The company has stated its intent to advance global licensing (out-licensing) discussions with global pharmaceutical companies based on the accumulated clinical data, alongside expected domestic revenue generation upon conditional approval.

All of these plans, however, remain subject to timing adjustments depending on regulatory review outcomes and subsequent clinical progress.

Valuation

PER

21.2×

PBR

4.5×

ROE

24.8%

EPS

₩602

BPS

₩2,819

Dividend per share

₩0

Cellbion appears to be a case where expectations for clinical and regulatory progress of its pipeline are substantially reflected in its market capitalization, even as commercial revenue has yet to materialize meaningfully.

On a self-calculated basis, the price-to-book ratio trades at a significant premium to net assets, a pattern commonly observed among clinical-stage biotech companies without an established earnings base.

The trailing four-quarter sum of net income turned superficially positive, aided by a large non-operating item in Q2 2026, even though operating results remained in cumulative loss over the same period, making conventional profitability metrics difficult to apply at face value.

The company does not pay dividends, so shareholder return through dividends offers limited appeal at this stage. Because differences in calculation methodology can exist between self-calculated figures and official exchange statistics, such differences should be considered when comparing per-share metrics.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Favorable Clinical Data Versus the Competing Drug

Phase 2 data presented at 2026 ASCO/ASCO-GU showed an objective response rate of 35.9%, exceeding the competing drug Novartis' Pluvicto, while radiographic progression-free survival reached 11.04 months in a pure monotherapy setting without any combination benefit, well above Pluvicto's 8.7 months.

Complete response rates and the incidence of dry mouth (xerostomia) were also reported to be comparatively favorable. Such data could serve as a favorable basis for the conditional approval review and future global partnering discussions.

Early Commercialization Path via Expedited Review

The MFDS designated the related candidate as an orphan drug and a globally innovative product eligible for expedited review, creating an institutional framework allowing conditional marketing approval based on Phase 2 results alone, without a Phase 3 trial.

The company filed for conditional approval in December 2025 under this framework, and if the process proceeds smoothly, commercialization could be accelerated. This could shorten the cash-burn period relative to a conventional post-Phase-3 approval pathway.

Combination Trial Collaboration With a Global Pharma

The company has a clinical trial collaboration and supply agreement with MSD (Merck) for a Keytruda combination regimen, having secured approval for a related Phase 1 trial protocol in September 2025.

Such early-stage collaboration with a major global pharma company could strengthen negotiating leverage in future indication expansion or licensing discussions. That said, many specific terms and the scope of any future expansion of the collaboration have not yet been disclosed.

Bear factors

Widening Operating Losses and Cash Burn Every Year

The operating loss widened every year, from KRW -5.04 billion in 2023 to KRW -8.24 billion in 2025, while operating cash outflow also grew from KRW -3.94 billion to KRW -5.55 billion over the same period. Revenue remains small at around KRW 2 billion, still insufficient to offset losses. Any delay in commercialization could increase the need for additional financing.

Uncertainty Over the Timing of Final Conditional Approval

The company filed for conditional approval in December 2025 and has stated a target of launching within 2026, but as of reports from May 2026 the review was described only as 'proceeding as planned,' with no subsequently confirmed disclosure of final approval identified.

Regulatory review timelines could be delayed relative to expectations or altered by requests for additional data. With the final approval timing uncertain, the timing of eventual revenue generation also remains fluid.

Difficulty Interpreting Earnings Quality

In Q2 2026, despite a widening operating loss, owner net income swung sharply positive to KRW 14.40 billion, a divergence that appears attributable to non-operating factors rather than the core business.

As a result, the trailing four-quarter sum of net income was superficially positive, though it is difficult to interpret this as profit generated from actual operations. Given this characteristic, care is needed before applying conventional net-income-based metrics directly to evaluate the company.

Risk factors

Regulatory Risk

Both the conditional marketing approval and the Phase 3 IND for the core pipeline depend on MFDS review outcomes, with possible delays, requests for additional data, or changes in approval conditions.

Because the conditional approval is based on Phase 2 results, failure to meet subsequent Phase 3 data requirements could affect the maintenance of that approval. This could delay the timing of revenue generation itself.

Competitive Risk

The global market is already anchored by Novartis' Pluvicto, and domestically, Futurechem competes with a similar radiopharmaceutical that has secured approval as Korea's 43rd domestically developed new drug.

As a later entrant, the company still faces the challenge of securing competitiveness in pricing, supply stability, and reimbursement listing. Intensifying competition could be a downside factor for expected revenue estimates.

Financing and Dilution Risk

The company decided to issue KRW 25 billion in privately placed convertible bonds, and in April 2026 completed the payment for 762,859 convertible preferred shares, increasing paid-in capital. Amid persistent operating losses and cash burn, continued external financing could dilute existing shareholders.

Where a large volume of convertible securities remains outstanding, the pace of future share count increases also warrants attention.

What to watch next

Around November 2026 (expected Q3 earnings disclosure)
Check the Q3 2026 revenue and operating loss trend, and whether further disclosure clarifies the nature of the large non-operating item seen in Q2 2026.
Timing to be confirmed (upon MFDS conditional approval decision)
Confirm whether the conditional marketing approval for '177Lu-pocuvotide' filed in December 2025 is finally granted, and if so, the domestic launch schedule.
Timing to be confirmed (upon Phase 3 IND review outcome)
Check whether the domestic Phase 3 IND filed on June 30, 2026 is approved, and when patient enrollment begins.
Timing to be confirmed (upon disclosure of MSD combination trial progress)
Monitor whether early safety/efficacy data or further progress updates are disclosed following the first dosing in the MSD Keytruda combination trial.
Timing to be confirmed (upon any licensing-related disclosure)
Check whether the global out-licensing discussions the company said it is pursuing based on accumulated clinical data progress into a concrete agreement or disclosure.

Overall view

Cellbion is at a stage of pursuing conditional approval and a Phase 3 IND simultaneously for its prostate cancer radiopharmaceutical 'pocuvotide,' running commercialization and follow-on clinical work in parallel.

Phase 2 metrics such as ORR and rPFS were favorably assessed relative to the competing drug, but the final timing of conditional approval has not been officially confirmed as of the search date.

Financially, revenue remains small and operating losses and cash burn have widened each year, while Q2 2026 saw a temporary swing to positive net income driven by a large non-operating item disconnected from operating results, placing the company in a range that is difficult to interpret using conventional profitability metrics.

The collaboration with MSD on a combination trial points to potential mid-to-long-term partnering, though it has not yet been confirmed to have translated into concrete outcomes.

The outcomes of the conditional approval and Phase 3 IND reviews, along with the earnings structure in subsequent quarters, are likely to be key variables going forward. Readers should verify the progress of the checkpoints above directly before forming any investment judgment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.